CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma

Am J Clin Pathol. 2009 Oct;132(4):531-8. doi: 10.1309/AJCP7E5ASGOENPFP.

Abstract

We studied the expression of cytokeratin (CK) 7, CK20, CDX-2, and p16 in 119 cervical adenocarcinomas (65 usual type [50 invasive; 15 in situ], 37 intestinal type [21 invasive; 16 in situ], 10 endometrioid, 5 adenosquamous, and 2 signet-ring carcinomas) in comparison with 55 cases of rectal adenocarcinomas. The percentage of cells staining was considered negative if 0% to 5% stained; more than 5% was considered positive. For p16, staining of more than 50% was considered positive. CK7 was expressed in all cervical cases and in 12 rectal adenocarcinomas (22%). CK20 was expressed in 17 cervical adenocarcinomas (14.3%) and in 48 rectal adenocarcinomas (87%). CK20 immunostaining was diffuse in the majority of rectal tumors but focal in most cervical tumors. CDX-2 was expressed in all cases of rectal adenocarcinoma and in 46 cervical adenocarcinomas (38.7%): usual type, 10 (15%); intestinal type, 31 (84%); endometrioid type, 5 (50%); adenosquamous and signet-ring types, 0 (0%). CDX-2 is a marker for intestinal differentiation irrespective of a rectal or cervical origin. Therefore, it should not be used as the sole basis to confirm the colorectum as the primary origin in metastatic cases.

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / physiopathology*
  • CDX2 Transcription Factor
  • Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis
  • Female
  • Homeodomain Proteins / biosynthesis*
  • Humans
  • Intestinal Neoplasms / physiopathology
  • Keratin-20 / biosynthesis
  • Keratin-7 / biosynthesis
  • Rectal Neoplasms / physiopathology
  • Trans-Activators / biosynthesis*
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / physiopathology*

Substances

  • CDX2 Transcription Factor
  • Cyclin-Dependent Kinase Inhibitor p16
  • Homeodomain Proteins
  • Keratin-20
  • Keratin-7
  • Trans-Activators